<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of complications of peptic ulcer disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of complications of peptic ulcer disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of complications of peptic ulcer disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nimish B Vakil, MD, AGAF, FACP, FACG, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David I Soybel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H62849741">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of peptic ulcer disease (PUD) include bleeding, penetration, perforation, and gastric outlet obstruction. This topic will provide an overview of the complications of PUD and their general management. The specific management of complicated PUD, the endoscopic management of peptic ulcer bleeding, and the surgical approaches to complications of PUD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8040.html" rel="external">
          "Surgical management of peptic ulcer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H73185785">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H4116224401">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of complications in patients with chronic PUD is 2 to 3 percent per year. There has been a consistent decrease in the incidence of bleeding and perforation and hospitalization rates due to complications of PUD, presumably reflecting the fall in
         <em>
          Helicobacter pylori
         </em>
         prevalence [
         <a href="#rid1">
          1,2
         </a>
         ]. As an example, in the United States there has been a 30 to 40 percent fall in hospitalizations for PUD complications between 1993 and 2006 [
         <a href="#rid3">
          3
         </a>
         ]. Similar data have been reported in other countries [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/22.html" rel="external">
          "Peptic ulcer disease: Epidemiology, etiology, and pathogenesis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         In the United States, bleeding is the most common complication of PUD (73 percent), followed by perforation (9 percent), and obstruction (3 percent) [
         <a href="#rid3">
          3
         </a>
         ]. A large systematic review estimated that the annual incidence of peptic ulcer hemorrhage ranges from 19 to 57 cases per 100,000 individuals, and that the annual incidence of ulcer perforation ranges from 4 to 14 cases per 100,000 individuals [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H623903379">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with bleeding peptic ulcer, the majority of deaths are related to multi-organ failure or cardiopulmonary causes rather than to bleeding itself [
         <a href="#rid6">
          6
         </a>
         ]. Not surprisingly, in patients with gastrointestinal bleeding requiring endoscopic therapy, hypovolemic shock, multiple co-morbidities, and rebleeding in the hospital were predictive of mortality [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         In patients undergoing surgery for perforated PUD, the long-term mortality is high, with one in three patients dying in the follow-up period. Older age, co-morbid illnesses, and post-operative complications were predictors of mortality [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Penetration of an ulcer into adjacent organs is a rare complication of PUD in the era of proton pump inhibitors [
         <a href="#rid9">
          9
         </a>
         ]. Penetration occurs in descending order of frequency into the pancreas, lesser omentum, biliary tract, liver, greater omentum, mesocolon, colon, and vascular structures. Gastric outlet obstruction is the least frequent complication of PUD in developed countries. Most cases are associated with duodenal or pyloric channel ulceration. (See
         <a class="medical medical_review" href="/z/d/html/2621.html" rel="external">
          "Gastric outlet obstruction in adults", section on 'Peptic ulcer disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H56805017">
         <span class="h2">
          Risk factors for ulcer complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications can occur in patients with PUD due to any etiology. However,
         <em>
          H. pylori
         </em>
         infection and nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , are the primary causes of ulcer bleeding and perforation [
         <a href="#rid10">
          10-13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/22.html" rel="external">
          "Peptic ulcer disease: Epidemiology, etiology, and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H381597610">
         <span class="h3">
          H. pylori infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          H. pylori
         </em>
         infection increases the risk of peptic ulcer bleeding in NSAID and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         users but not in patients on anticoagulants such as
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         .
         <em>
          H. pylori
         </em>
         infection also increases the risk of bleeding in patients on non-aspirin antiplatelet therapy and combination antiplatelet therapy with aspirin [
         <a href="#rid14">
          14
         </a>
         ].
         <em>
          H. pylori
         </em>
         infection has also been associated with perforated peptic ulcer [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3866145946">
         <span class="h3">
          NSAID use
         </span>
        </p>
        <p class="headingAnchor" id="H1114639350">
         <span class="h4">
          Drug- and dose-specific risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The magnitude of the risk of PUD complications associated with NSAIDs vary by the specific drug and are also dose dependent [
         <a href="#rid5">
          5
         </a>
         ]. As an example, in a study of 2777 patients, the overall relative risk (RR) of bleeding associated with NSAID use was 5.3 (95% CI 4.5-6.2). However, the risk varied by drug and was lowest for aceclofenac (RR 3.1, 95% CI 2.3-4.2) and was highest for
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         (RR 14.4, 95% CI 5.2-39.9) [
         <a href="#rid16">
          16
         </a>
         ]. The risk was higher in patients taking high-dose NSAIDs compared with those taking medium- or low-dose NSAIDs (RR 6.8, 95% CI 5.3-8.8 versus RR 4.0, 95% CI 3.2-5.0). The risk was highest in the first 30 days of NSAID use (RR 7.6, 95% CI 6.0-9.5). The risk remained high between days 31 and 90 days (RR 7.3, 95% CI 4.0-13.2), but dropped after 91 days (RR 2.6, 95% CI 1.6-4.1).
        </p>
        <p class="headingAnchor" id="H3872017342">
         <span class="h4">
          Use of concomitant medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concomitant use of anticoagulants, antiplatelet agents, corticosteroids, and other NSAIDs, including low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , increase the risk of ulcer complications [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H128139601">
         <span class="h4">
          Concurrent H. pylori infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          H. pylori
         </em>
         infection is both an independent and synergistic risk factor for bleeding PUD in patients on NSAIDs [
         <a href="#rid17">
          17-19
         </a>
         ]. A meta-analysis of nine case-control studies that assessed the prevalence of
         <em>
          H. pylori
         </em>
         infection and NSAID use in patients with peptic ulcer bleeding suggested that the
         <em>
          H. pylori
         </em>
         infection combined with NSAID use increases the risk of bleeding above that associated with either risk factor alone [
         <a href="#rid20">
          20
         </a>
         ]. The analysis found that individually, the odds ratios for bleeding peptic ulcers associated with
         <em>
          H. pylori
         </em>
         and NSAID use were 1.8 and 4.9, respectively, whereas the odds ratio increased to 6.1 when both
         <em>
          H. pylori
         </em>
         and NSAID were present.
        </p>
        <p class="headingAnchor" id="H3221315129">
         <span class="h4">
          Other risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important risk factor for ulcer complications in patients on NSAIDs is a prior history of clinical ulcer disease or ulcer complications. Other risk factors for NSAID-induced peptic ulcer complications include advanced age (&gt;65 years) and chronic debilitating disorders, especially cardiovascular disease [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H56805506">
         <span class="h3">
          Ulcer characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory ulcers, giant ulcers (&gt;2 cm), and pyloric channel ulcers are associated with higher complications rates. (See
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease", section on 'Refractory peptic ulcer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4258079309">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         While most patients may have typical ulcer symptoms prior to the development of complications, there is a subset of patients with silent ulcers and are only brought to medical attention due to peptic ulcer complications.
        </p>
        <p class="headingAnchor" id="H2749600414">
         <span class="h2">
          Bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bleeding from peptic ulcers may present with hematemesis (either red blood or coffee-ground emesis), or melena (black, tarry stool). In rare cases, patients have massive bleeding and present with hematochezia (red or maroon blood in the stool) and orthostatic hypotension. (See
         <a class="medical medical_review" href="/z/d/html/2644.html" rel="external">
          "Causes of upper gastrointestinal bleeding in adults", section on 'Peptic ulcer disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H117192768">
         <span class="h2">
          Gastric outlet obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ulcers located in the pyloric channel or duodenum can cause gastric outlet obstruction. Symptoms include early satiety, bloating, nausea, vomiting, epigastric pain shortly after eating, and weight loss. Prolonged vomiting and poor fluid intake may lead to hypokalemia and hypochloremic metabolic alkalosis. (See
         <a class="medical medical_review" href="/z/d/html/2621.html" rel="external">
          "Gastric outlet obstruction in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H842512297">
         <span class="h2">
          Penetration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with penetrating ulcers often present with a change in symptoms due to symptomatic involvement of adjacent structures.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrocolic or duodenocolic fistulas can present with halitosis, feculent vomiting, postprandial diarrhea, dyspepsia, and weight loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Penetration into a surrounding organ can result in a perivisceral abscess.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erosion into vascular structures can result in gastrointestinal hemorrhage (eg, aortoenteric fistula or erosion into the cystic artery) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erosion into the biliary tree can result in a choledochoduodenal fistula that can cause hemobilia and/or extrahepatic biliary obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fistulization into the pancreatic duct [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H365487672">
         <span class="h2">
          Perforation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of perforation is lower than previously reported, ranging from 3 to 6.5 per 100,000 individuals  (
         <a class="graphic graphic_diagnosticimage graphicRef81661" href="/z/d/graphic/81661.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid23">
          23,24
         </a>
         ]. Prepyloric gastric ulcerations account for most perforations followed by duodenal bulb ulcers [
         <a href="#rid25">
          25
         </a>
         ]. Ulcer perforation should be suspected in patients who suddenly develop severe, diffuse abdominal pain. The classic triad of sudden onset of abdominal pain, tachycardia, and abdominal rigidity is the hallmark of peptic ulcer perforation. If the perforation is walled off, if the gastric fluid is confined by fibrosis, or if the perforation is retroperitoneal, symptoms may be much less severe as compared with free intraperitoneal perforations. In such cases, the upper abdominal pain is more insidious, the presentation often delayed, and the abdominal examination is frequently equivocal. (See
         <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">
          "Overview of gastrointestinal tract perforation", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3590715500">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific complications of PUD are often suspected based on a change in pattern of existing symptoms or development of new symptoms. As examples, the development of hematemesis, melena, or hematochezia suggest an ulcer bleed; nausea, vomiting, and epigastric pain shortly after eating suggest a gastric outlet obstruction; and sudden onset of abdominal pain, tachycardia, and abdominal rigidity are suggestive of a perforation. The diagnosis is established by endoscopic evaluation and/or abdominal imaging. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H923838357">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4460472">
         <span class="h2">
          General management
         </span>
        </p>
        <p class="headingAnchor" id="H4460481">
         <span class="h3">
          Supportive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive measures include fluid resuscitation based on the hemodynamic status, correction of associated electrolyte abnormalities, and blood transfusions in selected patients with gastrointestinal bleeding. Patients should be kept fasting in anticipation of endoscopic or surgical intervention. Early surgical consultation allows for preoperative preparation should urgent surgical intervention become necessary. (See
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults", section on 'General management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults", section on 'Hemodynamically unstable patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4460489">
         <span class="h3">
          Acid suppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with active peptic ulcer bleeding (eg, hematemesis, hemodynamic instability) should receive initial acid suppressive therapy with an intravenous (IV) proton pump inhibitor (PPI; eg,
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         80 mg bolus). Typically, endoscopy is performed on these patients within 12 hours. However, if endoscopy is delayed, a second dose of an IV PPI should be given 12 hours later (eg, esomeprazole 40 mg). For patients who may have stopped bleeding (eg, patients who are hemodynamically stable with melena), we give an IV PPI every 12 hours (eg, esomeprazole 40 mg). Subsequent dosing will then depend on presence of high-risk stigmata of recent hemorrhage on endoscopic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers", section on 'Acid suppression'
         </a>
         .)
        </p>
        <p>
         In patients with other peptic-ulcer-related complications (gastric outlet obstruction, penetration, perforation), high-dose twice-daily PPI treatment is reasonable to enhance healing (eg, oral
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg twice daily), but dosing should generally be reduced to once daily after four weeks [
         <a href="#rid26">
          26-28
         </a>
         ].
        </p>
        <p>
         The duration of treatment is based on the ulcer location and underlying etiology. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Duration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4460572">
         <span class="h3">
          Discontinue NSAIDs
         </span>
         <span class="headingEndMark">
          —
         </span>
         If
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can be discontinued, even complicated ulcers readily heal and uncommonly recur. If non-aspirin NSAIDs must be continued, the incidence of recurrent PUD can be decreased by switching to a COX-2 inhibitor with concomitant therapy with a PPI or
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         (for rare patients who are unable to take PPIs or have contraindications to PPI use). Likewise, when continued low-dose aspirin is justified, concomitant cotherapy with a PPI is indicated. Strategies for secondary prevention of gastroduodenal toxicity due to NSAIDs are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14.html" rel="external">
          "NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H806587914">
         <span class="h3">
          Evaluation for H. pylori
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be evaluated for
         <em>
          H. pylori.
         </em>
         Eradication of
         <em>
          H. pylori
         </em>
         dramatically reduces recurrent ulcers and complications.
         <em>
          H. pylori
         </em>
         testing (eg, biopsy urease test, urea breath test) in the setting of ulcer bleeding or PPI use may result in false-negative results, so repeat testing is required for patients whose initial tests are negative [
         <a href="#rid10">
          10
         </a>
         ]. A urea breath test for
         <em>
          H. pylori
         </em>
         performed as soon as the patient has resumed oral feedings is a reasonably sensitive predictor of
         <em>
          H. pylori
         </em>
         infection.
        </p>
        <p>
         We typically defer treatment of
         <em>
          H. pylori
         </em>
         with oral antibiotics until patients are tolerating oral feedings. Interrupted treatment may encourage resistance and should be avoided. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Diagnostic tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3813649906">
         <span class="h2">
          Management of specific complications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding
         </strong>
         – Upper endoscopy is the best initial diagnostic and therapeutic procedure in the management of bleeding peptic ulcers. Surgery and transcatheter arteriography/intervention are generally reserved for patients with failed therapeutic endoscopy. The management of patients with bleeding peptic ulcers is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penetrating ulcers
         </strong>
         – Management of penetrating ulcers should follow the intensive measures outlined for refractory ulcers. (See
         <a class="medical medical_review" href="/z/d/html/27.html" rel="external">
          "Approach to refractory peptic ulcer disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perforation
         </strong>
         – Many ulcer-related perforations of the stomach and duodenum require surgical repair (open or laparoscopic). However, nonoperative management may be used is selective patients. The management of gastric and duodenal perforations and surgical repair of PUD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">
          "Overview of gastrointestinal tract perforation", section on 'Initial management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8040.html" rel="external">
          "Surgical management of peptic ulcer disease", section on 'Perforated gastric ulcer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric outlet obstruction
         </strong>
         – Initial management consists of acid suppression with a parenteral PPI, avoidance of NSAIDs and, if present, eradication of
         <em>
          H. pylori
         </em>
         infection. In patients who fail to respond to a brief (three to seven day) trial of conservative management, endoscopic dilation is indicated. Surgery is reserved for patients with a complete pyloric obstruction that cannot be safely dilated, or if the obstruction persists or recurs despite endoscopic management. (See
         <a class="medical medical_review" href="/z/d/html/2621.html" rel="external">
          "Gastric outlet obstruction in adults", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2126425343">
         <span class="h1">
          SUBSEQUENT MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H56806712">
         <span class="h2">
          Upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upper endoscopy is indicated for most patients with PUD who present with a PUD complication in order to exclude neoplasia, unless there is confidence that the ulcer site was adequately evaluated and biopsied endoscopically or surgically at the time of presentation. To allow ulcers to heal, upper endoscopy is performed after 8 to 12 weeks. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Repeat upper endoscopy in selected patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2621.html" rel="external">
          "Gastric outlet obstruction in adults", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H193857306">
         <span class="h2">
          Prevention of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of complicated PUD is for the recurrence of complications unless the underlying cause can be treated. Strategies to reduce the risk of recurrence include NSAID avoidance and eradication of
         <em>
          H. pylori
         </em>
         . The decision to continue maintenance antisecretory therapy varies based on the patient and ulcer characteristics and risk factors for recurrent PUD. Strategies to decrease the risk of recurrent PUD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Prevention of recurrence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11767021">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The major complications of peptic ulcer disease (PUD) include perforation, gastric outlet obstruction, penetration, and bleeding. The risk of complications in patients with chronic PUD has been decreasing due to
         <em>
          Helicobacter pylori
         </em>
         eradication and widespread use of proton pump inhibitors (PPIs). There has been a decrease in the incidence of bleeding and perforation and hospitalization rates due to complications of PUD, presumably reflecting the fall in
         <em>
          H. pylori
         </em>
         prevalence. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          H. pylori
         </em>
         and nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , are the primary causes of ulcer bleeding and perforation. Other risk factors for ulcer complications include refractory, giant (&gt;2 cm), and pyloric channel ulcers. (See
         <a class="local">
          'Risk factors for ulcer complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While most patients may have typical ulcer symptoms prior to the development of complications, a subset of patients have silent ulcers and are brought to medical attention due to peptic ulcer complications. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific complications of PUD are often suspected based on a change in pattern of existing symptoms or development of new symptoms. As examples, the development of hematemesis, melena, or hematochezia suggest an ulcer bleed; nausea, vomiting, and epigastric pain shortly after eating suggest a gastric outlet obstruction; sudden onset of abdominal pain, tachycardia, and abdominal rigidity are suggestive of a perforation. Endoscopic evaluation and/or abdominal imaging are needed to establish the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General measures for all patients with peptic ulcer-related complications include fluid resuscitation based on the hemodynamic status, correction of associated electrolyte abnormalities, and high-dose intravenous PPI therapy. Blood transfusions may be required in selected patients with gastrointestinal bleeding. Additional measures are specific to the type of complication. (See
         <a class="local">
          'Management of specific complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upper endoscopy is indicated in most patients with PUD who present with a complication, except those with perforation, in order to exclude neoplasia. To allow for ulcer healing, upper endoscopy is typically repeated after 8 to 12 weeks. (See
         <a class="local">
          'Upper endoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The natural history of complicated PUD is for the recurrence of complications unless the underlying cause can be treated. Strategies to reduce the risk of recurrence include NSAID avoidance and eradication of
         <em>
          H. pylori.
         </em>
         The decision to continue maintenance antisecretory therapy varies based on the patient and ulcer characteristics and risk factors for recurrent PUD. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Prevention of recurrence'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H448421734">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Andrew H Soll, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sadic J, Borgström A, Manjer J, et al. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009; 30:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashinskaya B, Nahed BV, Redjal N, et al. Trends in Peptic Ulcer Disease and the Identification of Helicobacter Pylori as a Causative Organism: Population-based Estimates from the US Nationwide Inpatient Sample. J Glob Infect Dis 2011; 3:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg 2010; 251:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011; 84:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung JJ, Tsoi KK, Ma TK, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010; 105:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu PW, Ng EK, Cheung FK, et al. Predicting mortality in patients with bleeding peptic ulcers after therapeutic endoscopy. Clin Gastroenterol Hepatol 2009; 7:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorsen K, Søreide JA, Søreide K. Long-Term Mortality in Patients Operated for Perforated Peptic Ulcer: Factors Limiting Longevity are Dominated by Older Age, Comorbidity Burden and Severe Postoperative Complications. World J Surg 2017; 41:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibukawa N, Ouchi S, Wakamatsu S, et al. A Rare Case of Gastric Ulcer Penetrating the Pancreas that was Successfully Managed by Conservative Therapy. Intern Med 2017; 56:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Delgado J, Gené E, Suárez D, et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011; 106:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000; 231:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisbert JP, Legido J, García-Sanz I, Pajares JM. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis 2004; 36:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Mittal GS, Gupta S, et al. Prevalence of Helicobactor pylori in patients with perforated duodenal ulcer. Trop Gastroenterol 2004; 25:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venerito M, Schneider C, Costanzo R, et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CS, Chia CF, Lee HC, et al. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. J Surg Res 2013; 182:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santolaria S, Lanas A, Benito R, et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999; 13:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okan A, Tankurt E, Aslan BU, et al. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study. J Gastroenterol Hepatol 2003; 18:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin KJ, García Rodríguez LA, Hernández-Díaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf 2011; 20:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasumarthy L, Kumar RR, Srour J, Ahlbrandt D. Penetration of Gastric Ulcer into the Splenic Artery: A Rare Complication. Gastroenterology Res 2009; 2:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorsen K, Søreide JA, Kvaløy JT, et al. Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality. World J Gastroenterol 2013; 19:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson CH, McLean RC, McCallum I, et al. An evaluation of the epidemiology, management and outcomes for perforated peptic ulcers across the North of England over 15 years: A retrospective cohort study. Int J Surg 2019; 64:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaba EA, Klair T, Ikedilo O, Vemulapalli P. A 10-Year Review of Surgical Management of Complicated Peptic Ulcer Disease From a Single Center: Is Laparoscopic Approach the Future? Surg Laparosc Endosc Percutan Tech 2016; 26:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau JY, Barkun A, Fan DM, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013; 381:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11:iii.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 24 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508403" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22224001" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trends in Peptic Ulcer Disease and the Identification of Helicobacter Pylori as a Causative Organism: Population-based Estimates from the US Nationwide Inpatient Sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20009753" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205256" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The changing face of hospitalisation due to gastrointestinal bleeding and perforation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21494041" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755976" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955161" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Predicting mortality in patients with bleeding peptic ulcers after therapeutic endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27734076" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Long-Term Mortality in Patients Operated for Perforated Peptic Ulcer: Factors Limiting Longevity are Dominated by Older Age, Comorbidity Burden and Severe Postoperative Complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28794357" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A Rare Case of Gastric Ulcer Penetrating the Pancreas that was Successfully Managed by Conservative Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21304499" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10674604" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15002818" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15682658" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of Helicobactor pylori in patients with perforated duodenal ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29655196" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23158404" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687434" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10571609" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12519219" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929396" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11809181" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21626606" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27990205" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Penetration of Gastric Ulcer into the Splenic Artery: A Rare Complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372356" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30872174" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : An evaluation of the epidemiology, management and outcomes for perforated peptic ulcers across the North of England over 15 years: A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27661205" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A 10-Year Review of Surgical Management of Complicated Peptic Ulcer Disease From a Single Center: Is Laparoscopic Approach the Future?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23746903" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Challenges in the management of acute peptic ulcer bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29475806" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18021578" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
